Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: A European randomized, controlled clinical trial

Giuseppe Mancia, Antonio Coca, Irina Chazova, Xavier Girerd, Hermann Haller, Paolo Pauletto, Danuta Pupek-Musialik, Yevgeniya Svyshchenko

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES:: The aim of this study was to evaluate the efficacy and safety of combinations of lercanidipine (L) and enalapril (E) at different doses on office and home blood pressure (BP) in patients with Stage 2 hypertension. STUDY DESIGN:: This was a randomized, double-blind, placebo-controlled, factorial study conducted in 100 centres from seven countries. Patients with office DBP 100-109 mmHg and home DBP at least 85 mmHg at the end of a 2-week placebo run-in period were randomized to a 10-week treatment with placebo, L (10 or 20 mg), E (10 or 20 mg) or the four L-E combinations. The efficacy parameters were office DBP at trough (primary), SBP at trough and home SBP and DBP. Office BP was measured at each visit in both the sitting and the standing position, while home BP was measured twice in the morning and twice in the evening for at least 3 days before treatment and at study end. Safety parameters included adverse events, laboratory tests and 12-lead ECG. RESULTS:: A total of 1039 patients were randomized (48% men, mean age 54 years, mean BMI 30 kg/m, 40% obese patients). Baseline BP was similar in all groups and lower for home than for office values (149/95 and 159/103 mmHg, respectively). A marked placebo effect was observed on office but not on home BP. Combination therapy was superior to placebo at all doses for both office and home BP. The greatest effect was observed in the L20/E20 group, in which the SBP/DBP fall amounted to -19.2/-15.2 and -13.2/-7.5 mmHg for sitting office and home BP, respectively. Similar reductions were observed on standing office BP. The L20/E20 combination was associated with less cough, palpitations and leg oedema than monotherapies, with no increased rate of dizziness or hypotension. CONCLUSION:: In Stage 2 hypertension, a fixed-dose combination of L and E ensures a control of both office and out-of-office BP, with a favourable tolerability profile.

Original languageEnglish
Pages (from-to)1700-1707
Number of pages8
JournalJournal of Hypertension
Volume32
Issue number8
DOIs
Publication statusPublished - 2014

Keywords

  • combination therapy
  • enalapril
  • essential hypertension (Stage 2)
  • factorial study design
  • home blood pressure
  • lercanidipine

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: A European randomized, controlled clinical trial'. Together they form a unique fingerprint.

Cite this